Radionetics Oncology’s Post

The growth of the global radiopharmaceutical market is driving healthcare innovation and scientific advancements, leading to improved diagnostic and therapeutic solutions. This expansion is also expected to significantly increase market valuation, reflecting a broader adoption in medical practices. Innovation + Growth = nextgen medications which ultimately drive improved patient outcomes. The ultimate Win Win.

From a rising number of randomized trials to utilizing biomarker endpoints, oncology programs have become increasingly complex. Find out the latest trends in oncology trial design from our blog https://ow.ly/I1Tv50QkEjn

Radiopharmaceuticals and theranostics have become an emerging trend in the industry. One such therapeutic area that has seen an exponential jump in the use of theranostics is oncology. Learn more in our latest blog here: https://lnkd.in/g2TwBa9a

With 46 regulatory approvals across 14 indications over the last three years, IQVIA’s expert oncology team brings innovation to your oncology development – allowing you to increase predictability, focus on the patient, and manage trial complexity. Explore our oncology capabilities. https://bit.ly/3rk8tFa #OncologyDevelopment #RegulatoryApprovals #Innovation #PatientFocus #TrialComplexity #ClinicalResearch

SkillAscend Kaushalam Vruddhayati Chronicles: Glenmark Teams Up With Beigene To Revolutionize Oncology Treatment In India. Read the full article to learn how Glenmark is partnering with BeiGene to bring cutting-edge oncology treatments to India. “Unlocking The Healing Stories Of Tomorrow” #pharmaNews #GlenmarkBeigene #OncologyDrugs #SkillAscendChronicles

Among the various #biomarkers, which ones will help your oncology program? Find out in our blog: https://bit.ly/3TfQERh

Among the various #biomarkers, which ones will help your oncology program? Find out in our blog: https://bit.ly/3TfQERh

Among the various #biomarkers, which ones will help your oncology program? Find out in our blog: https://bit.ly/3TfQERh

The Cancer Moonshot initiative in 2017 spurred a new paradigm in oncology drug development. Learn more about the impact these new regulatory projects are having for patients, physicians, and developers in my recently published article.

With 46 regulatory approvals across 14 indications over the last three years, IQVIA’s expert oncology team brings innovation to your oncology development – allowing you to increase predictability, focus on the patient, and manage trial complexity. Explore our oncology capabilities. https://bit.ly/466JQtU #oncology #regulatory #clinicaltrials